Sign inJoin waitlistJoin the waitlist

Amer Zeidan

Chief, Division of Hematologic Malignancies · Yale Cancer Center

Credentials: · · · · · · ·

History

Division of Hematologic Malignancies · Yale Cancer Center
Present
Early Therapeutics Research · Yale Cancer Center
Present
Leukemia and Myeloid Malignancies Program · Yale Cancer Center
Present

Johns Hopkins University
2013–2014
Johns Hopkins Hospital
2012–2013
Johns Hopkins Hospital
2010–2013
Internal Medicine
Rochester General Hospital
2007–2010
Johns Hopkins University
University of Jordan Faculty of Medicine
1997–2001

Research

Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges
Review · Blood Reviews · 2019 · Last of 5 authors · Corresponding · 717 citations
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
New England Journal of Medicine · 2020 · 449 citations
Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study
The Lancet Haematology · 2021 · 305 citations

Jan Bewersdorf
129 papers · 111 as a resident
Maximilian Stahl
105 papers
RS
Rory Shallis
89 papers
SG
Steven Gore
87 papers
Nikolai Podoltsev
85 papers · 28 as a resident
RK
Rami Komrokji
75 papers
Mikkael Sekeres
52 papers
Scott Huntington
44 papers · 1 as a fellow
AD
Amy DeZern
37 papers
Michael Savona
36 papers
Guillermo Garcia-Manero
35 papers
Gail Roboz
29 papers

Grants

Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $229.5K · Yale University
1997–2029

Clinical trials

BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia
Principal investigator · Active not recruiting · Phase 2
National Cancer Institute (NCI)
2021–2027
BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia
Principal investigator · Active not recruiting · Phase 2
National Cancer Institute (NCI)
2021–2027
GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia
Principal investigator · Terminated · Phase 2
Yale University
2019–2020
Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
Principal investigator · Active not recruiting · Phase 2
ECOG-ACRIN Cancer Research Group
2019–2031